As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment The change from baseline ...

Inhibition of complement fragment C5a with an investigational drug called avacopan demonstrated efficacy against antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and might provide an ...

Avacopan, an investigational oral inhibitor of complement activation, is efficacious and safe for treating antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis, based on the results of the ...

Avacopan treatment for antineutrophil cytoplasmic antibody–associated vasculitis demonstrated lower rates of adverse events, serious adverse events, white blood cell (WBC) count reductions, and ...

An investigational C5a receptor inhibitor, avacopan, was effective as a steroid-sparing induction treatment for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in a phase III trial ...

ChemoCentryx management is still delivering strong execution. Despite the recent announcement that the LUMINA-1 trial failed to meet its primary endpoint, there are many upcoming catalysts for ...

Please provide your email address to receive an email when new articles are posted on . “ANCA-associated vasculitis is associated with increased early mortality and a high risk of end-stage renal ...

The appraisal committee considered evidence submitted by CSL Vifor, a review of this submission by the evidence review group (ERG), and responses from stakeholders. See the committee papers for full ...

Pivotal trial demonstrated avacopan’s statistical superiority in sustaining remission at 52 weeks over the glucocorticoid-containing standard-of-care therapy MOUNTAIN VIEW, Calif., June 03, 2020 ...